Treatment alternatives for Mycobacterium kansasii | Zendy

John R. Graybill | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment alternatives for Mycobacterium kansasii

Author(s) -

John R. Graybill

Publication year - 2001

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/47.4.417

Subject(s) - mycobacterium kansasii , ethambutol , rifapentine , medicine , azithromycin , antagonism , antibacterial agent , pharmacology , mycobacterium tuberculosis , antibiotics , microbiology and biotechnology , tuberculosis , biology , latent tuberculosis , pathology , receptor

Mycobacterium kansasii was administered intravenously to congenitally athymic (nude) mice. Beginning 1 week later, rifapentine, azithromycin, ethambutol or combined therapy was initiated orally. All three drugs were highly active individually. Although there was no evidence of antagonism, combined therapy was not more effective than either component used alone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research